Table 1. Baseline patient characteristics.
| Characteristics | RA (n = 64) | PsA (n = 30) | AS (n = 20) |
|---|---|---|---|
| Age | 57 (28–79) | 50 (23–78)* | 49 (30–72)¥ |
| Rheumatic disease duration, years | 2 (0–30) | 3 (0–37) | 3 (0–40) |
| Male (gender), n (%) | 17 (27) | 17 (57)* | 16 (80)¥ |
| Current smokers, n (%) | 20 (31) | 7 (23) | 10 (50) |
| Hypertension, n (%) | 17 (27) | 7 (23) | 6 (30) |
| Diabetes mellitus, n (%) | 3 (5) | 0 (0) | 1 (5) |
| Methotrexate, n (%) | 34 (53) | 16 (53) | 0 (0)ɸ¥ |
| Endothelial dysfunction, n (%) | 23 (36) | 8 (27) | 9 (45) |
| PTX 3 (ng/mL) | 3.8 (1.2–22.1) | 4.2 (1.1–14.7) | 4.0 (1.9–8.5) |
| CRP (mg/L) | 8 (1–78) | 5 (1–99) | 10 (1–157) |
| WBC (109/L) | 7.25 (3.7–11.3) | 6.3 (4.2–11.3) | 7.9 (4.7–12.3)ɸ |
| ESR (mm/h) | 18.5 (1–81) | 7 (2–48)* | 9.5 (2–87) ¥ |
| Total Cholesterol (mmol/L) | 5.2 (2.8–8.7) | 5.3 (3.8–7.1) | 4.9 (2.9–7.9) |
| LDL (mmol/L) | 3.2 (1.1–5.8) | 3.4 (2.4–4.9) | 2.8 (1.6–5.2) |
| HDL (mmol/L) | 1.4 (0.9–2.8) | 1.3 (0.7–2.9) | 1.25 (0.8–2.5) |
| Triglycerides (mmol/L) | 1.2 (0.5–2.8) | 0.96 (0.6–3) | 1.25 (0.7–2.1) |
| HbA1C (%) | 5.7 (4.9–8.9) | 5.5 (4.6–6.4) | 5.6 (4.9–6.9) |
| Fasting serum glucose (mmol/L) | 5.1 (4.2–8.6) | 5.1 (4.4–6.9) | 5 (4.5–8.4) |
| Uric acid μmol/L | 271 (151–499) | 296 (152–566) | 310 (182–410) |
| BMI (kg/m2) | 26 (19–41) | 26 (19–39) | 28 (22–36) |
| Previously used DMARDs, n (%) | 40 (63) | 15 (50) | 2 (10) |
| MHAQ | 0.65 (0–1.45) | 0.40 (0.05–1.55) | 0.43 (0–1.40) |
| PGA ¤ | 38(7–73) | 21 (0–57)* | 26 (3–60)¥ |
| PtGA ¤ | 52 (5–98) | 44 (2–96) | 56 (6–96) |
| Number of swollen joints | 6 (0–28) | 2 (0–8)* | 0 (0–6)¥ɸ |
| BASDAI | - | 4.7 (0.3–9.5) | 5.1 (0.9–9.6) |
| BASFI | - | 3,1(0–7.2) | 4.1 (1.1–7.6) |
| BASMI | - | - | 3 (0–10) |
| DAS 28 | 4.98 (2.6–7.3) | - | - |
Unless indicated otherwise, values are given as median (range).
RA, rheumatoid arthritis; PsA, psoriatic arthritis; AS, ankylosing spondylitis; PTX3, pentraxin 3; CRP, C-reactive protein; WBC, white blood cells; ESR, erythrocyte sedimentation rate; LDL, low-density lipoprotein; HDL, High-density lipoprotein; HbA1C, glycated haemoglobin; BMI, body mass index; MHAQ, Medical Health Assessment Questionnaire; PGA, Physicians' Global Assessment Score of disease activity; PtGA, Patients' Global Assessment Score of disease activity; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; DAS 28, Disease Activity Score for 28 joints.
* p< 0.01 for comparisons between the RA group and the PsA group.
¥ p< 0.01 for comparisons between the RA group and the AS group.
ɸ p< 0.01 for comparisons between the PsA group and the AS group.
¤ On a 100-mm visual analog scale.